All News

Patients with relapsed/refractory mantle cell lymphoma described by one expert as “older, sicker and more heavily pretreated” than those previously studied experienced impressive responses to treatment with CAR-T cell therapy Tecartus.

An expert discusses three crucial conversations about cancer care that patients should have with their health care providers.

Exploring holistic therapies can yield some interesting findings and benefits.

Researchers have found the CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) to be a cost-effective second-line treatment for patients with relapsed and refractory diffuse large B-cell lymphoma as the drug’s cost rises.

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta.

Buddha once said, “To keep the body in good health is a duty... otherwise we shall not be able to keep our mind strong and clear.”

A patient in a phase 2 trial has received the first dose of a novel cancer vaccine plus Keytruda for solid skin cancer tumors.

The first patients has been dosed within the new CLARIFY trial for patients with prostate cancer awaiting prostatectomy.

The moment when I was told that my immune deficiency and rare cancer were linked.

The Food and Drug Administration stopped enrollment on a clinical trial evaluating LN-145 TIL for non-small cell lung cancer after a patient on the trial died.

From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.

The phase 2a MYLOX-1 trial demonstrated fibrosis reduction in some patients with myelofibrosis who previously received treatment with Jakafi (ruxolitinib).

I never thought I’d say it, but I miss my padded bras.

The top stories on chronic lymphocytic leukemia from 2023 included topics like BTK inhibitors, minimal residual disease status and approaches to care for various stages of the disease.

The pharmaceutical company submitted applications for the FDA to consider approval of Rybrevant plus lazertinib for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858 substitution mutations.

Lessons happen when you least expect it.

Dr. Stephanie Berg of Dana-Farber Cancer Institute and Harvard Medical School discusses the need to be mindful of quality of life when treating prostate cancer.

Managing a cancer support group isn't easy.

Experts look back on the year in the news regarding bispecific antibodies for the treatment of B-cell lymphomas including CLL and SLL.

Research focuses on the importance of quality of life and nutritional needs for patients with breast cancer.

Cancer. Such an expansive topic.

Diet and exercise can benefit patients with cancer through side effect management and improved outcomes. CURE provides an overview of the most-read diet and exercise stories of 2023.

The RELATIVITY-123 trial evaluating Opdualag in metastatic microsatellite stable colorectal cancer ended prematurely, according to the drug’s manufacturer.

Menin inhibitors for patients with AML have been one of many improvements within the blood cancer space this year, Lee Greenberger of the Leukemia and Lymphoma Society told CURE®.

Today I had lunch with a good friend only to learn his next-door neighbor lost her fight with lung cancer two days ago.

Obtaining molecular genotyping results before first-line treatment resulted in better outcomes for patients with non-small cell lung cancer, an expert explained.

Thomas Silver discusses how a community of support helped a patient when his bone marrow transplant was delayed.

The FDA granted priority review of patritumab deruxtecan for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or more systemic therapies.